[ ignore, parking something ]
Inventor(s):
Vogelstein; Bert , Baltimore, MD
Kinzler; Kenneth W. , Baltimore, MD
Sherman; Michael I. , Glen Ridge, NJ
Applicant(s):
The John Hopkins University, Baltimore, MD
PharmaGenics, Inc., Allendale, NJ
Issued/Filed Dates:
Nov. 8, 1994 / March 31, 1992
Application Number:
US1992000860758
IPC Class:
C12Q 001/68;
Class:
Current: 435/006; 435/320.1; 536/024.1; 536/024.31;
Original: 435/006; 435/320.1; 536/024.1; 536/024.31; 424/002;
Field of Search:
435/5,6,7.1,7.21,7.23,7.92,7.94,70.3,272,975,320.1 436/501,518,63,64,811,813 424/002
536/23.1,24.31,24.1
Government Info:
This work was partially supported by the U.S. government under NIH grants CA06973, CA09243,
CA35494, CA09071 and CA43460. The U.S. government retains certain rights in this invention.
Priority Number(s):
March 31, 1992
US1992000860758
Family
Abstract:
Specific sequences in the human genome are the sites of strong binding of wild-type p53 protein, but
not mutant forms of the protein. These sequences are used diagnostically to detect cells in which the
amount of wild-type p53 is diminished. The sequences can also be used to screen for agents which
correct for loss of wild-type p53 to DNA in cancer cells.
Attorney, Agent, or
Firm:
Banner, Birch, McKie & Beckett;
Primary/Assistant
Examiners:
Nucker; Christine M.; Scheiner; Laurie
Related Applications:
Application Number
ApplDate
Patent
Issued
Title
US1991000715182
1991-06-14
U.S. References:
none
First Claim:
We claim:
1. A method of pre-screening agents for use in cancer therapy, comprising: measuring the amount of
binding of a p53 protein encoded by a mutant gene found in cancer cells of a patient to a DNA molecule
which conforms to the consensus binding site having more than one monomer of the double-stranded
sequence RRRCWWGYYY;
measuring the amount of binding of said p53 protein to said DNA molecule in the presence of a
test substance; and
comparing the amount of binding of the p53 protein in the presence of said test substance to the
amount of binding of the p53 protein in the absence of said test substance, a test substance
which increases the amount of binding being a candidate for use in cancer therapy. |
